clinical trial · NCT07822880
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
Eli Lilly and Company·phase4·not yet recruiting·n = 30
Thyroid NeoplasmsCarcinoma, Non-Small-Cell LungSelpercatinib
brief summary
This study will evaluate the safety of selpercatinib in participants with RET-altered cancers in India. The study will also assess the number of changes and why participants stop study treatment. For each participant, the study is expected to last 56 weeks and will include up to 16 protocol-specific visits.
started
Oct 1, 2026
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Sep 23, 2026
official title
A Phase 4, Single-Arm Study to Evaluate the Safety of Selpercatinib in Participants With RET-Altered Cancers in India
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol